The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

Özgüler, İbrahim Murat; Üstünel, Latif

doi:10.5455/annalsmedres.2020.04.305

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Olmesartan mediates the Nrf2/ HO-1 signaling pathway and promotes p38-MAPK translocation, improving inflammation control and lowering oxidative stress [18]. In patients undergoing cardiopulmonary bypass, Olmesartan treatment significantly decreases IL-6 levels, highlighting its anti-inflammatory efficacy [19]. Moreover, OLM shows potential in reducing ischemia-reperfusion injury by depleting inflammatory mediators such as TNF-α, MMP-9 (matrix metallopeptidase-9), IL-6, as well as apoptotic markers like BCL-2 and BAX [20].…”

Section: Inflammation Diseasementioning

confidence: 99%

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

Rind,

Mahmood,

Siddiqui

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug’s established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan’s versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug’s favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts.

show abstract

Section: Inflammation Diseasementioning

confidence: 99%

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

Rind,

Mahmood,

Siddiqui

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

“…In patients undergoing cardiopulmonary bypass, Olmesartan treatment significantly decreases IL-6 levels, highlighting its anti-inflammatory efficacy [19]. Moreover, OLM shows potential in reducing ischemia-reperfusion injury by depleting inflammatory mediators such as TNF-α, MMP-9 (matrix metallopeptidase-9), IL-6, as well as apoptotic markers like BCL-2 and BAX [20].…”

Section: Inflammation Diseasementioning

confidence: 99%

Untitled

2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

Cited by 2 publications

References 0 publications

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

From Hypertension to Beyond: Unraveling the Diverse Mechanisms of Olmesartan in Disease Modulation

Untitled

Contact Info

Product

Resources

About